A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors

Molecular Pharmacology

Volumn 84, Issue 6, 2013, Pages 854-864

  Michino, Mayako ^a   Donthamsetti, Prashant ^b,c   Beuming, Thijs ^d   Banala, Ashwini ^e   Duan, Lihua ^b,c   Roux, Thomas ^f   Han, Yang ^b,c   Trinquet, Eric ^f   Newman, Amy Hauck ^e   Javitch, Jonathan A ^b,c   Shi, Lei ^a,g  

^a Department of Obstetrics Gynecology   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d SCHRÖDINGER INC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Cisbio Bioassays ^*  (France)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYLPIPERAZINE DERIVATIVE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; AMIDE; BINDING PROTEIN; CARVEDILOL; CYANOPINDOLOL; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ETICLOPRIDE; GLYCINE;

ARTICLE; BINDING ASSAY; CHIMERA; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; EXTRACELLULAR LOOP 1; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; SITE DIRECTED MUTAGENESIS;

BINDING SITES; BINDING, COMPETITIVE; GLYCINE; HEK293 CELLS; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; PIPERAZINES; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECOMBINANT FUSION PROTEINS;

EID: 84888863473     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087833     Document Type: Article

References (47)

1. Abel R, Young T, Farid R, Berne BJ, and Friesner RA (2008) Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J Am Chem Soc 130: 2817-2831.
2. Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, and Lamarque L et al. (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol 6 :587-594.
3. Ballesteros JA, Shi L, and Javitch JA (2001) Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 60:1-19.
4. Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, and Newman AH (2011) N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J Med Chem 54:3581-3594.
5. Beuming T, Che Y, Abel R, Kim B, Shanmugasundaram V, and Sherman W (2012) Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization. Proteins 80:871-883.
6. Beuming T, Farid R, and Sherman W (2009) High-energy water sites determine peptide binding affinity and specificity of PDZ domains. Protein Sci 18 :1609-1619.
7. Boeckler F and Gmeiner P (2006) The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacol Ther 112:281-333.
8. 2 receptor agonists. J Med Chem 55:7141-7153.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, and Cherezov V et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330:1091-1095.
11. Cho AE, Guallar V, Berne BJ, and Friesner R (2005) Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. J Comput Chem 26 :915-931.
12. Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, and Shaw DE (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 108:13118-13123.
13. Ehrlich K, Götz A, Bollinger S, Tschammer N, Bettinetti L, Härterich S, Hübner H, Lanig H, and Gmeiner P (2009) Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. J Med Chem 52:4923-4935.
14. Feig M, Karanicolas J, and Brooks CL, 3rd (2004) MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graph Model 22:377-395.
15. Felts AK, Harano Y, Gallicchio E, and Levy RM (2004) Free energy surfaces of beta-hairpin and alpha-helical peptides generated by replica exchange molecular dynamics with the AGBNP implicit solvent model. Proteins 56:310-321.
16. Gilson MK and Zhou HX (2007) Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 36:21-42.
17. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, and Newman AH (2007) Heterocyclic analogues of N-(4-(4-(2,3- dichlorophenyl) piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem 50:4135-4146.
18. Guo W, Shi L, and Javitch JA (2003) The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem 278:4385-4388.
19. Hann MM and Keserü GM (2012) Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 11:355-365.
20. Heidbreder CA and Newman AH (2010) Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci 1187:4-34.
21. Holmes A, Lachowicz JE, and Sibley DR (2004) Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology 47:1117-1134.
22. Huggins DJ, Sherman W, and Tidor B (2012) Rational approaches to improving selectivity in drug design. J Med Chem 55:1424-1444.
23. Javitch JA, Fu D, and Chen J (1995) Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. Biochemistry 34:16433-16439.
24. Katritch V, Cherezov V, and Stevens RC (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33:17-27.
25. Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E, Green HF, Liu T, Chae PS, and Dror RO et al. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482:552-556.
26. Mason JS, Bortolato A, Congreve M, and Marshall FH (2012) New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci 33:249-260.
27. Munson PJ and Rodbard D (1988) An exact correction to the "Cheng-Prusoff" correction. J Recept Res 8:533-546.
28. Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, Levy B, Cao J, Michino M, and Luedtke RR et al. (2012a) Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem 55:6689-6699.
29. Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, and Skolnick P (2012b) Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 84:882-890.
30. Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, and Luedtke RR (2009) N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl) butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem 52:2559-2570.
31. Osguthorpe DJ, Sherman W, and Hagler AT (2012) Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols. J Phys Chem B 116:6952-6959.
32. Patriksson A and van der Spoel D (2008) A temperature predictor for parallel tempering simulations. Phys Chem Chem Phys 10:2073-2077.
33. Robarge MJ, Husbands SM, Kieltyka A, Brodbeck R, Thurkauf A, and Newman AH (2001) Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl] alkylfluorenyl-carboxamides as novel ligands selective for the dopamine D3 receptor subtype. J Med Chem 44:3175-3186.
34. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, and Sunahara RK et al. (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature 469:236-240.
35. Rosenkilde MM, Benned-Jensen T, Frimurer TM, and Schwartz TW (2010) The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 31:567-574.
36. Sansom MS and Weinstein H (2000) Hinges, swivels and switches: the role of prolines in signalling via transmembrane alpha-helices. Trends Pharmacol Sci 21:445-451.
37. Segaloff DL (2012) Regulatory processes governing the cell surface expression of LH and FSH receptors. Subcell Biochem 63:113-129.
38. Sherman W, Day T, Jacobson MP, Friesner RA, and Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534-553.
39. Shi L, Simpson MM, Ballesteros JA, and Javitch JA (2001) The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 40:12339-12348.
40. Simpson MM, Ballesteros JA, Chiappa V, Chen J, Suehiro M, Hartman DS, Godel T, Snyder LA, Sakmar TP, and Javitch JA (1999) Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. Mol Pharmacol 56: 1116-1126.
41. Sugita Y and Okamoto Y (1999) Replica-exchange molecular dynamics method for protein folding. Chem Phys Lett 314:141-151.
42. Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, and Jacobson KA (2012) Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem 55:4847-4860.
43. Visiers I, Braunheim BB, and Weinstein H (2000) Prokink: a protocol for numerical evaluation of helix distortions by proline. Protein Eng 13:603-606.
44. Warne T, Edwards PC, Leslie AG, and Tate CG (2012) Crystal structures of a stabilized b1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20:841-849.
45. Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, and Tate CG (2011) The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor. Nature 469:241-244.
46. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, and Schertler GF (2008) Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454:486-491.
47. Zhou R, Berne BJ, and Germain R (2001) The free energy landscape for beta hairpin folding in explicit water. Proc Natl Acad Sci USA 98:14931-14936.